1. ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder
- Author
-
Annarita Di Nunzio, Francesco Trepiccione, Pizza A, Giovanni Conzo, Tommaso Cicchella, Alessandra F. Perna, Marco Raffaelli, Luigi Santini, Miriam Zacchia, Rocco Domenico Alfonso Bellantone, Diego Ingrosso, Perna, Alessandra, Pizza, Alessandra, Di Nunzio, Annarita, Bellantone, Rocco, Raffaelli, Marco, Cicchella, Tommaso, Conzo, Giovanni, Santini, Luigi, Zacchia, Miriam, Trepiccione, Francesco, and Ingrosso, Diego
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Settore MED/18 - CHIRURGIA GENERALE ,030232 urology & nephrology ,Medicine (miscellaneous) ,ADAM17 Protein ,urologic and male genital diseases ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Chronic kidney disease-mineral and bone disorder ,Renal Dialysis ,Internal medicine ,Nutrition and Dietetic ,Medicine ,Humans ,Klotho Proteins ,Glucuronidase ,Uremia ,Chronic Kidney Disease-Mineral and Bone Disorder ,Kidney ,Metalloproteinase ,Hyperparathyroidism ,Nutrition and Dietetics ,business.industry ,Tumor Necrosis Factor-alpha ,Hydrogen-Ion Concentration ,medicine.disease ,female genital diseases and pregnancy complications ,Fibroblast Growth Factors ,Fibroblast Growth Factor-23 ,030104 developmental biology ,medicine.anatomical_structure ,Endocrinology ,C-Reactive Protein ,Nephrology ,Parathyroid Hormone ,Case-Control Studies ,Secondary hyperparathyroidism ,Hyperparathyroidism, Secondary ,business ,Primary hyperparathyroidism - Abstract
The triad composed by α-Klotho, fibroblast growth factor-23, and its receptor are involved in the pathogenesis of chronic kidney disease–mineral and bone disorder. A disintegrin and metalloproteinase 17 (ADAM17) is a metalloproteinase causing the proteolytic shedding of α-Klotho from the cell membrane, and its role in chronic kidney disease–mineral and bone disorder is not yet known. We studied the circulating levels of the above-mentioned mediators in patients with secondary hyperparathyroidism due to uremia, compared to control subjects, as well as in patients with primary hyperparathyroidism. We also measured the immunofluorescence pattern of the relevant tissue proteins in specimens obtained from patients undergoing parathyroid surgery for secondary compared to primary hyperparathyroidism. Results showed that α-Klotho tissue levels are reduced, in the presence of increased ADAM17 tissue levels. In addition, we showed increased serum levels of the main product of ADAM17 proteolytic activity, tumor necrosis factor-α. Thus, we found a paradoxical situation, in secondary compared to primary hyperparathyroidism, that is, that in the face of increased tumor necrosis factor-α in circulation, both soluble and tissue α-Klotho are reduced significantly, despite increased tissue ADAM17. In conclusion, tissue and serum levels of α-Klotho seem to have become independent from the regulation induced by ADAM17, which constitutes therefore another tassel in the impaired α-Klotho–FGF23 receptor axis present in uremia.
- Published
- 2017